This site is intended for health professionals only
Wednesday 20 March 2019
Share |

Selincro enters the market in Spain

Selincro is indicated for the reduction of alcohol consumption in certain adult patients.
Adult drinker

Biotie, the specialised drug development company focused on products for neurodegenerative and psychiatric disorders, has announced that its partner Lundbeck has launched Selincro in Spain.
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification.
According to the terms of the licence agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of €2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine